- Packman, Seymour;
- Germain, DP;
- Charrow, J;
- Desnick, RJ;
- Guffon, N;
- Kempf, J;
- Lachmann, RH;
- Lemay, R;
- Linthorst, GE;
- Ronald, C
Background: Fabry disease results from deficient α-galactosidase A activity and globotriaosylceramide accumulation causing renal insufficiency, strokes, hypertrophic cardiomyopathy and early demise. We assessed the 10-year outcome of recombinant α-galactos
